Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A European healthcare consortium of fifteen members comprised of a publicly founded organization, governmental entities, academic teams and biotech companies, including Mymetics was awarded E7.50 million grant from the European Commission within the context of the EU's seventh framework program.
Subscribe to our email newsletter
The consortium will investigate new human immunodeficiency virus (HIV) antigen formulations for triggering broadly neutralizing antibodies in the blood and mucosal compartments, using various adjuvants and platform technologies based on virus-like particles. Mymetics will support this European consortium through its expertise with vaccination and HIV mucosal immune response, and will provide access to the HIV virosomes technology.
Sylvain Fleury, chief scientific officer and vice-president of Mymetics, said: “The increasing interest for mucosal protection against HIV and the HIV-virosome technology platform are opening new horizons in HIV vaccination. We are looking forward to discovering viably-promising candidate vaccines emerging from this four-year program.”